Articles tagged "Epstein-Barr virus (EBV)"

2022 American Transplant Congress
PTLD Suspected by Visualization of Atypical Urinary Lymphocytes
J. Huidobro E¹, F. Anghileri², P. Troncoso³, A. Huete⁴, P. Downey¹
¹Nephrology, Pontificia Universidad Catolica de Chile, Santiago, Chile, ²Clinical Laboratories, Pontificia Universidad Catolica de Chile, Santiago, Chile, ³Urology, Pontificia Universidad Catolica de Chile, Santiago, Chile, ⁴Radiology, Pontificia Universidad Catolica de Chile, Santiago, Chile
*Purpose: Urinalysis has been used for the detection of acute rejection but visualization of atypical lymphocytes in the urine sediment as an early sign of…
2022 American Transplant Congress
Pre-Emptive Rituximab Use for Epstein-Barr Virus (EBV) Viremia in Cardiothoracic Solid Organ Transplant Recipients
B. Astorga, A. Loethen, L. Potter
University of Chicago Medicine, Chicago, IL
*Purpose: EBV viremia is associated with potentially life-threatening post-transplant lymphoproliferative disorders (PTLD) after solid organ transplantation. The utility of rituximab for treating EBV viremia in…
2022 American Transplant Congress
Use of Targeted T-Cell Therapy (Posoleucel) for the Treatment of Epstein-Barr Virus Associated Leiomyosarcoma in an Adult Kidney Transplant Recipient: A Case Report
R. Saranu¹, S. Nikiforow², V. Jo³, H. So², P. Stowe², S. Tripathi¹, F. Cardarelli⁴, A. Chandraker¹
¹Renal Division, Brigham and Women's Hospital, Boston, MA, ²Dana Farber Cancer Institute, Boston, MA, ³Pathology, Brigham and Women's Hospital, Boston, MA, ⁴Allovir, Cambridge, MA
*Purpose: Epstein-Barr virus (EBV)-associated leiomyosarcomas (EBV+LMS) are neoplasms rarely seen in solid organ transplant (SOT) recipients and currently lack effective treatment options. We present a…
2022 American Transplant Congress
Combined Metagenomic Viral Detection and Donor-Derived Cell-Free DNA Quantification for Solid Organ Transplant Recipients
R. Sinha¹, C. Rebello², E. Bixler¹, A. Al-Turck¹, A. Berg¹, J. Friedewald², S. Kleiboeker¹
¹Eurofins Viracor, Lees Summit, MO, ²Northwestern University, Chicago, IL
*Purpose: Solid organ transplant recipients are predisposed to opportunistic infections, and current viral diagnostic methods focus on sensitive detection of single pathogens by qPCR. However,…
2022 American Transplant Congress
Post Transplant Virologic Outcomes in DCD Kidney Transplant Recipients Treated with Thymoglobulin Induction Immunosuppression and Maintenance Belatacept vs Calcineurin Inhibitor Therapy
T. Engebretsen¹, M. Kueht¹, A. Lea², M. Mujtaba³
¹Abdominal Transplant Surgery, University of Texas Medical Branch, Galveston, TX, ²Infectious Disease, University of Texas Medical Branch, Galveston, TX, ³Nephrology, University of Texas Medical Branch, Galveston, TX
*Purpose: Belatacept is an inhibitor of the T-Cell costimulatory pathway that can be used in recipients of Donation after Circulatory Death (DCD) where the intended…
2022 American Transplant Congress
Clinical Outcomes of Solid Organ Transplant (SOT) Patients with Epstein-Barr Virus-Driven (EBV⁺) Post-Transplant Lymphoproliferative Disease (PTLD) Who Fail Rituximab Plus Chemotherapy: A Multinational, Retrospective Chart Review Study
V. Dharnidharka¹, D. Thirumalai², U. Jaeger³, W. Zhao², D. Dierickx⁴, P. Xun², P. Minga⁵, A. Sawas⁶, N. Sadetsky⁷, P. Chauvet⁸, E. Sundaram⁹, A. Barlev⁷, H. Zimmermann¹⁰, R. U. Trappe¹⁰
¹Washington University School of Medicine/St Louis Children’s Hospital, St Louis, MO, ²Atara Biotherapeutics, Thousand Oaks, CA, ³Medical University of Vienna, Vienna, Austria, ⁴Universitair Ziekenhuis Leuven, Leuven, Belgium, ⁵Niguarda Ca’ Granda Hospital, Milan, Italy, ⁶Herbert Irving Comprehensive Cancer Center, Department of Medicine, CUMC, New York, NY, ⁷Atara Biotherapeutics, South San Francisco, CA, ⁸Service des Maladies du Sang, CHU Lille, Lille, France, ⁹Nashville Biosciences, Nashville, TN, ¹⁰DIAKO Bremen, Bremen, Germany
*Purpose: EBV+ PTLD patients (pts) following SOT who fail rituximab + chemotherapy (CT) have poor outcomes with limited treatment options. Published data on clinical outcomes…
2022 American Transplant Congress
EBV+ PTLD Tumor MicroRNAs Detected in Circulating Extracellular Vesicles Are Decreased in Pediatric Transplant Recipients with EBV+ PTLD
A. Sen¹, J. Enriquez¹, M. Rao¹, M. Glass¹, Y. Balachandran¹, S. Syed¹, C. Twist¹, K. Weinberg¹, S. D. Boyd¹, D. Bernstein¹, A. Trickey¹, D. Gratzinger¹, B. Tan¹, M. G. Lapasaran¹, M. A. Robien², M. Brown³, B. Armstrong⁴, M. Sever⁴, D. Desai⁵, G. Mazariegos⁶, C. Chin⁷, T. Fishbein⁸, R. S. Venick⁹, A. Tekin¹⁰, H. Zimmermann¹¹, R. U. Trappe¹², C. O. Esquivel¹, O. M. Martinez¹, S. M. Krams¹
¹Stanford U, Palo Alto, CA, ²NIH, Bethesda, MD, ³NIAID, Bethesda, MD, ⁴Rho, Durham, NC, ⁵UT Southwestern, Dallas, TX, ⁶Pittsburgh U, Pittsburgh, PA, ⁷CCHMC, Cincinnati, OH, ⁸Georgetown U, Washington, DC, ⁹UCLA, LA, CA, ¹⁰Miami U, Miami, FL, ¹¹DIAKO Ev. Diakonie-Krankenhaus, Bremen, Germany, ¹²Charité - Universitätsmedizin, Berlin, Germany
*Purpose: Post-transplant lymphoproliferative disorder (PTLD) is a serious complication of solid organ transplantation. Predisposing factors for PTLD include primary Epstein-Barr virus (EBV) infection in children,…
2022 American Transplant Congress
Pre-Emptive Rituximab to Prevent Post Transplant Lymphoproliferative Disorder (PTLD) in Pediatric Kidney Transplant Recipients with EBV DNAemia: A Case Series from the Pediatric Nephrology Research Consortium (PNRC)
I. Ashoor¹, S. Ranabothu², S. Al-Akash³, A. Moudgil⁴, Y. Shi⁴, S. Kizilbash⁵, D. Puliyanda⁶, V. Dharnidharka⁷
¹LSU Health Sciences Center New Orleans, New Orleans, LA, ²Arkansas Children's Hospital, Little Rock, AR, ³Driscoll Children's Hospital, Corpus Christie, TX, ⁴Children's National Medical Center, Washington, DC, ⁵University of Minnesota Medical Center, Minneapolis, MN, ⁶Cedars-Sinai Medical Center, Los Angeles, CA, ⁷Washington University in St. Louis, St Louis, MO
*Purpose: The use of Rituximab (RTX) to prevent PTLD in patients with EBV DNAemia is an established strategy in hematopoietic stem cell transplants, but with…
2021 American Transplant Congress
Gain of Function Mutations in Latent Membrane Protein 1 of Epstein Barr Virus are Associated with Increased Risk of Post-Transplant Lymphoproliferative Disorder
O. M. Martinez¹, S. M. Krams¹, M. Robien², M. Lapasaran¹, M. Arvedson¹, K. Weinberg¹, S. Boyd¹, B. Armstrong³, C. Twist⁴, D. Gratzinger¹, B. Tan¹, A. Trickey¹, M. Sever³, M. Brown², D. Bernstein¹, C. O. Esquivel¹
¹Stanford University Sch of Med, Stanford, CA, ²NIAID, Rockville, MD, ³Rho, Durham, NC, ⁴Roswell Park, Buffalo, NY
*Purpose: Post-transplant lymphoproliferative disorder (PTLD) remains a serious problem in the pediatric transplant population. Clinical Trials of Organ Transplantation in Children (CTOTC)-06 is a prospective…
2021 American Transplant Congress
Impact of High-Risk EBV Discordance Status on Survival Outcomes in Kidney Transplant Recipients: A Multivariable Analysis
A. Dinesh¹, S. Jackson², T. L. Pruett¹, S. Riad³
¹Division of Transplantation, Department of Surgery, University of Minnesota, Minneapolis, MN, ²Biostatistics, Analytics Consulting Services- Solid Organ Transplant, M Health Fairview, Minneapolis, MN, ³Department of Medicine, University of Minnesota, Minneapolis, MN
*Purpose: High-risk EBV discordance has been linked to Post-Transplant Lymphoproliferative Disorder (PTLD) after kidney transplantation; however, the impact on recipient and graft survival is under-reported.…

1
2
3
…
10
Next Page »